Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

<< Previous
Bullboard Posts
Next >>
Post by clutchbeyerson Jan 18, 2021 11:59am
454 Views
Post# 32320136

My Perspective: Sernovas Cell Pouch Market Share

My Perspective: Sernovas Cell Pouch Market Share

The world has been waiting for a functional cure to insulin regulatuon for Type 1 Diabetes for a long time. Knowing what friends go through with insulin injections, calculations, etc....its mind blowing that insulin is the best we have. 

Already showing efficacy and safety signs in both animals and now human trials, the cell puch harnesses the ecosystem for cell therapy to do its work.

Now....look at the breadth of what cell therapy is set out to do, its far more than what Sernova publishes on the 3 scopes of its initial intent. This cell pouch has the cabability to be the standard for the cure of so much out there. 

And the best part? Thei cell pouch technology is trademarked and protected, so they have a cash-cow of a device protected from generics and other competitors to do something simiar. Not to mention they are all well behind in their research as compared to where Sernova is.

I wouldnt be surprised to see this in the 50-60 range in 1-2 years time once Phase 2 is near completion and Phase 3 is well undwerway. A buyout would push this to the 80-100 range at a minimum. I suspect Dr. Toleikis knows how massive this market share is for the future and will not give up this baby he put so much of his life into.

Good work longs!!!!! Enjoy this ride ;)

<< Previous
Bullboard Posts
Next >>